{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:05:58Z","timestamp":1790244358353,"version":"4.1.0"},"reference-count":455,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,24]],"date-time":"2027-09-24T00:00:00Z","timestamp":1821744000000},"content-version":"am","delay-in-days":327,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.pharmr.2026.100160","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T14:57:05Z","timestamp":1788533825000},"page":"100160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The promise of biased ligands in therapeutics"],"prefix":"10.1016","volume":"78","author":[{"given":"Dylan S.","family":"Eiger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-2899","authenticated-orcid":false,"given":"Jeffrey S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-5040","authenticated-orcid":false,"given":"Sudarshan","family":"Rajagopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tips.2004.06.006","article-title":"Historical review: a brief history and personal retrospective of seven-transmembrane receptors","volume":"25","author":"Lefkowitz","year":"2004","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib2","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nrm2803","article-title":"Fine-tuning of GPCR activity by receptor-interacting proteins","volume":"10","author":"Ritter","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.cellsig.2005.08.010","article-title":"RGS proteins have a signalling complex: interactions between RGS proteins and GPCRs, effectors, and auxiliary proteins","volume":"18","author":"Abramow-Newerly","year":"2006","journal-title":"Cell Signal"},{"issue":"5751","key":"10.1016\/j.pharmr.2026.100160_bib4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/284017a0","article-title":"The role of hormone receptors and GTP-regulatory proteins in membrane transduction","volume":"284","author":"Rodbell","year":"1980","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib5","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.bi.56.070187.003151","article-title":"G proteins: transducers of receptor-generated signals","volume":"56","author":"Gilman","year":"1987","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib6","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1146\/annurev-biochem-062708-134043","article-title":"Structure-function relationships of the G domain, a canonical switch motif","volume":"80","author":"Wittinghofer","year":"2011","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nrm2299","article-title":"Heterotrimeric G protein activation by G-protein-coupled receptors","volume":"9","author":"Oldham","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/cells10030555","article-title":"Historical perspective of the G protein-coupled receptor kinase family","volume":"10","author":"Benovic","year":"2021","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1073\/pnas.83.5.1174","article-title":"Phosphodiesterase activation by photoexcited rhodopsin is quenched when rhodopsin is phosphorylated and binds the intrinsic 48-kDa protein of rod outer segments","volume":"83","author":"Wilden","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cellsig.2017.01.024","article-title":"GPCR desensitization: acute and prolonged phases","volume":"41","author":"Rajagopal","year":"2018","journal-title":"Cell Signal"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100160_bib11","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1016\/S0021-9258(18)48041-6","article-title":"Purification and characterization of the beta-adrenergic receptor kinase","volume":"262","author":"Benovic","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100160_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cellsig.2017.07.004","article-title":"G protein-coupled receptor kinases: past, present and future","volume":"41","author":"Komolov","year":"2018","journal-title":"Cell Signal"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib13","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1073\/pnas.0409532102","article-title":"Functional antagonism of different G protein-coupled receptor kinases for beta-arrestin-mediated angiotensin II receptor signaling","volume":"102","author":"Kim","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.tips.2008.05.006","article-title":"Location, location, location \u2026site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling","volume":"29","author":"Tobin","year":"2008","journal-title":"Trends Pharmacol Sci"},{"issue":"185","key":"10.1016\/j.pharmr.2026.100160_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2001707","article-title":"Distinct phosphorylation sites on the \u03b22-adrenergic receptor establish a barcode that encodes differential functions of beta-arrestin","volume":"4","author":"Nobles","year":"2011","journal-title":"Sci Signal"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/0014-5793(84)81221-1","article-title":"Light-induced binding of 48-kDa protein to photoreceptor membranes is highly enhanced by phosphorylation of rhodopsin","volume":"176","author":"K\u00fchn","year":"1984","journal-title":"FEBS Lett"},{"issue":"4962","key":"10.1016\/j.pharmr.2026.100160_bib17","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1126\/science.2163110","article-title":"Beta-arrestin: a protein that regulates beta-adrenergic receptor function","volume":"248","author":"Lohse","year":"1990","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100160_bib18","doi-asserted-by":"crossref","first-page":"17882","DOI":"10.1016\/S0021-9258(19)37125-X","article-title":"Beta-arrestin2, a novel member of the arrestin\/beta-arrestin gene family","volume":"267","author":"Attramadal","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100160_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ceb.2013.11.005","article-title":"Role of beta-arrestins and arrestin domain-containing proteins in G protein-coupled receptor trafficking","volume":"27","author":"Kang","year":"2014","journal-title":"Curr Opin Cell Biol"},{"issue":"5247","key":"10.1016\/j.pharmr.2026.100160_bib20","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1126\/science.271.5247.363","article-title":"Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization","volume":"271","author":"Ferguson","year":"1996","journal-title":"Science"},{"issue":"6599","key":"10.1016\/j.pharmr.2026.100160_bib21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/383447a0","article-title":"Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor","volume":"383","author":"Goodman","year":"1996","journal-title":"Nature"},{"issue":"5402","key":"10.1016\/j.pharmr.2026.100160_bib22","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1126\/science.283.5402.655","article-title":"Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes","volume":"283","author":"Luttrell","year":"1999","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib23","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1073\/pnas.041604898","article-title":"Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds","volume":"98","author":"Luttrell","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib24","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1146\/annurev.physiol.69.022405.154749","article-title":"Beta-arrestins and cell signaling","volume":"69","author":"DeWire","year":"2007","journal-title":"Annu Rev Physiol"},{"issue":"43","key":"10.1016\/j.pharmr.2026.100160_bib25","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2303794120","article-title":"Signal transduction at GPCRs: allosteric activation of the ERK MAPK by beta-arrestin","volume":"120","author":"Kahsai","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"52","key":"10.1016\/j.pharmr.2026.100160_bib26","doi-asserted-by":"crossref","first-page":"37332","DOI":"10.1074\/jbc.M113.510412","article-title":"Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding","volume":"288","author":"Kook","year":"2013","journal-title":"J Biol Chem"},{"issue":"5496","key":"10.1016\/j.pharmr.2026.100160_bib27","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1126\/science.290.5496.1574","article-title":"Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3","volume":"290","author":"McDonald","year":"2000","journal-title":"Science"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100160_bib28","doi-asserted-by":"crossref","first-page":"8969","DOI":"10.1074\/jbc.R115.713313","article-title":"The beta-arrestins: multifunctional regulators of G protein-coupled receptors","volume":"291","author":"Smith","year":"2016","journal-title":"J Biol Chem"},{"issue":"6676","key":"10.1016\/j.pharmr.2026.100160_bib29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/33458","article-title":"The beta2-adrenergic receptor interacts with the Na+\/H+-exchanger regulatory factor to control Na+\/H+ exchange","volume":"392","author":"Hall","year":"1998","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100160_bib30","doi-asserted-by":"crossref","first-page":"15023","DOI":"10.1074\/jbc.M113.473660","article-title":"Role of SAP97 protein in the regulation of corticotropin-releasing factor receptor 1 endocytosis and extracellular signal-regulated kinase 1\/2 signaling","volume":"288","author":"Dunn","year":"2013","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib31","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.010909.105705","article-title":"GPCR interacting proteins (GIPs) in the nervous system: roles in physiology and pathologies","volume":"50","author":"Bockaert","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib32","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0898-6568(01)00239-X","article-title":"G protein-coupled receptor interacting proteins: emerging roles in localization and signal transduction","volume":"14","author":"Brady","year":"2002","journal-title":"Cell Signal"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/procel\/pwad035","article-title":"Single transmembrane GPCR modulating proteins: neither single nor simple","volume":"15","author":"Wang","year":"2024","journal-title":"Protein Cell"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib34","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1016\/S0021-9258(18)53442-6","article-title":"A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model","volume":"268","author":"Samama","year":"1993","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100160_bib35","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/bph.13278","article-title":"Superagonism at G protein-coupled receptors and beyond","volume":"173","author":"Schrage","year":"2016","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib36","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.mce.2010.07.009","article-title":"When simple agonism is not enough: emerging modalities of GPCR ligands","volume":"331","author":"Smith","year":"2011","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1476-5381.1956.tb00006.x","article-title":"A modification of receptor theory","volume":"11","author":"Stephenson","year":"1956","journal-title":"Br J Pharmacol Chemother"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib38","first-page":"32","article-title":"Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory","volume":"99","author":"Ariens","year":"1954","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"1219","key":"10.1016\/j.pharmr.2026.100160_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc R Soc Lond B Biol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib40","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd3954","article-title":"Signalling bias in new drug discovery: detection, quantification and therapeutic impact","volume":"12","author":"Kenakin","year":"2013","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib41","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1124\/pr.114.008862","article-title":"International union of basic and clinical pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands","volume":"66","author":"Christopoulos","year":"2014","journal-title":"Pharmacol Rev"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib42","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1124\/pr.108.000992","article-title":"Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery","volume":"62","author":"Kenakin","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmr.2026.100160_bib43","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.coph.2016.07.010","article-title":"Allosteric communication pipelines in G-protein-coupled receptors","volume":"30","author":"Vaidehi","year":"2016","journal-title":"Curr Opin Pharmacol"},{"issue":"7712","key":"10.1016\/j.pharmr.2026.100160_bib44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-018-0259-z","article-title":"Structural insights into G-protein-coupled receptor allostery","volume":"559","author":"Thal","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41573-025-01139-y","article-title":"GPCR drug discovery: new agents, targets and indications","volume":"24","author":"Lorente","year":"2025","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmr.2026.100160_bib46","series-title":"Pharmacology in Drug Discovery and Development: Understanding Drug Response","author":"Deakin","year":"2017"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors","volume":"47","author":"May","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib48","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.tips.2007.06.008","article-title":"Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?","volume":"28","author":"Schwartz","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib49","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.tips.2018.05.001","article-title":"PAM-antagonists: a better way to block pathological receptor signaling?","volume":"39","author":"Kenakin","year":"2018","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pharmthera.2004.08.010","article-title":"Positive and negative allosteric modulation of metabotropic glutamate receptors: emerging therapeutic potential","volume":"104","author":"Kew","year":"2004","journal-title":"Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s12276-022-00760-w","article-title":"An aptamer agonist of the insulin receptor acts as a positive or negative allosteric modulator, depending on its concentration","volume":"54","author":"Yunn","year":"2022","journal-title":"Exp Mol Med"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.tips.2020.12.005","article-title":"Biased allosteric modulators: new frontiers in GPCR Drug Discovery","volume":"42","author":"Slosky","year":"2021","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tips.2006.01.008","article-title":"The quantitative analysis of drug-receptor interactions: a short history","volume":"27","author":"Colquhoun","year":"2006","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2026.100160_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.sbi.2021.04.006","article-title":"Illuminating the complexity of GPCR pathway selectivity: advances in biosensor development","volume":"69","author":"Wright","year":"2021","journal-title":"Curr Opin Struct Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib55","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/mol.106.026716","article-title":"Distinct signaling profiles of beta1 and beta2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy","volume":"70","author":"Galandrin","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrd.2017.229","article-title":"Biased signalling: from simple switches to allosteric microprocessors","volume":"17","author":"Smith","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib57","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrd3024","article-title":"Teaching old receptors new tricks: biasing seven-transmembrane receptors","volume":"9","author":"Rajagopal","year":"2010","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib58","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.tips.2007.06.009","article-title":"Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors","volume":"28","author":"Kenakin","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0165-6147(00)89032-X","article-title":"Agonist-receptor efficacy II: agonist trafficking of receptor signals","volume":"16","author":"Kenakin","year":"1995","journal-title":"Trends Pharmacol Sci"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100160_bib60","doi-asserted-by":"crossref","first-page":"10782","DOI":"10.1073\/pnas.1834556100","article-title":"Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2","volume":"100","author":"Wei","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib61","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41589-023-01292-8","article-title":"A community Biased Signaling Atlas","volume":"19","author":"Caroli","year":"2023","journal-title":"Nat Chem Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib62","doi-asserted-by":"crossref","first-page":"C887","DOI":"10.1152\/ajpcell.00449.2021","article-title":"GPCR systems pharmacology: a different perspective on the development of biased therapeutics","volume":"322","author":"Eiger","year":"2022","journal-title":"Am J Physiol Cell Physiol"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100160_bib63","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1111\/bph.15811","article-title":"Community guidelines for GPCR ligand bias: IUPHAR review 32","volume":"179","author":"Kolb","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib64","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cell.2018.12.005","article-title":"Angiotensin analogs with divergent bias stabilize distinct receptor conformations","volume":"176","author":"Wingler","year":"2019","journal-title":"Cell"},{"issue":"6480","key":"10.1016\/j.pharmr.2026.100160_bib65","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1126\/science.aay9813","article-title":"Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR","volume":"367","author":"Wingler","year":"2020","journal-title":"Science"},{"issue":"6072","key":"10.1016\/j.pharmr.2026.100160_bib66","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1126\/science.1215802","article-title":"Biased signaling pathways in beta2-adrenergic receptor characterized by 19F-NMR","volume":"335","author":"Liu","year":"2012","journal-title":"Science"},{"issue":"7694","key":"10.1016\/j.pharmr.2026.100160_bib67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nature25773","article-title":"Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor-Gs complex","volume":"555","author":"Liang","year":"2018","journal-title":"Nature"},{"issue":"7790","key":"10.1016\/j.pharmr.2026.100160_bib68","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-019-1902-z","article-title":"Activation of the GLP-1 receptor by a non-peptidic agonist","volume":"577","author":"Zhao","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib69","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1476-5381.2011.01648.x","article-title":"Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3","volume":"166","author":"Scholten","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib70","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2006.08.019","article-title":"Identification of CXCR3 receptor agonists in combinatorial small-molecule libraries","volume":"349","author":"Stroke","year":"2006","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib71","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.cell.2020.04.053","article-title":"\u03b2-arrestin-biased allosteric modulator of NTSR1 selectively attenuates addictive behaviors","volume":"181","author":"Slosky","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib72","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1021\/ml400176n","article-title":"Discovery of ML314, a brain-penetrant nonpeptidic \u03b2-arrestin-biased agonist of the neurotensin NTR1 receptor","volume":"4","author":"Peddibhotla","year":"2013","journal-title":"ACS Med Chem Lett"},{"issue":"45","key":"10.1016\/j.pharmr.2026.100160_bib73","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.1073\/pnas.1104807108","article-title":"Discovery of beta-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy","volume":"108","author":"Allen","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib74","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/2472555217699158","article-title":"A systematic approach to identify biased agonists of the apelin receptor through high-throughput screening","volume":"22","author":"McAnally","year":"2017","journal-title":"SLAS Discov"},{"issue":"7619","key":"10.1016\/j.pharmr.2026.100160_bib75","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature19112","article-title":"Structure-based discovery of opioid analgesics with reduced side effects","volume":"537","author":"Manglik","year":"2016","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib76","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.cell.2024.02.004","article-title":"Structure-based design of non-hypertrophic apelin receptor modulator","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib77","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1021\/acs.jmedchem.5b02008","article-title":"Docking screens for novel ligands conferring new biology","volume":"59","author":"Irwin","year":"2016","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nchembio.180","article-title":"Quantifying biogenic bias in screening libraries","volume":"5","author":"Hert","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib79","first-page":"1076","article-title":"Direct selection of DNA-encoded libraries for biased agonists of GPCRs on live cells","volume":"3","author":"Cai","year":"2023","journal-title":"JACS Apr"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib80","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/2472555217749847","article-title":"Agonists and antagonists of protease-activated receptor 2 discovered within a DNA-encoded chemical library using mutational stabilization of the Target","volume":"23","author":"Brown","year":"2018","journal-title":"SLAS Discov"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib81","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1073\/pnas.1620645114","article-title":"Allosteric \u201cbeta-blocker\u201d isolated from a DNA-encoded small molecule library","volume":"114","author":"Ahn","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cellsig.2017.05.002","article-title":"Translating in vitro ligand bias into in vivo efficacy","volume":"41","author":"Luttrell","year":"2018","journal-title":"Cell Signal"},{"issue":"703","key":"10.1016\/j.pharmr.2026.100160_bib83","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc5944","article-title":"Spatial bias in cAMP generation determines biological responses to PTH type 1 receptor activation","volume":"14","author":"White","year":"2021","journal-title":"Sci Signal"},{"issue":"7366","key":"10.1016\/j.pharmr.2026.100160_bib84","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature10361","article-title":"Crystal structure of the \u03b22 adrenergic receptor-Gs protein complex","volume":"477","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"issue":"47","key":"10.1016\/j.pharmr.2026.100160_bib85","doi-asserted-by":"crossref","first-page":"20565","DOI":"10.1073\/pnas.1012865107","article-title":"CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells","volume":"107","author":"J\u00e4hnichen","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"33","key":"10.1016\/j.pharmr.2026.100160_bib86","doi-asserted-by":"crossref","first-page":"20284","DOI":"10.1073\/pnas.2009029117","article-title":"Synthetic nanobodies as angiotensin receptor blockers","volume":"117","author":"McMahon","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib87","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41589-025-01896-2","article-title":"Development of an allosteric adhesion GPCR nanobody with therapeutic potential","volume":"21","author":"Zheng","year":"2025","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib88","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/s41467-020-15884-8","article-title":"Improved GPCR ligands from nanobody tethering","volume":"11","author":"Cheloha","year":"2020","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib89","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1038\/s41467-024-49068-5","article-title":"Highly biased agonism for GPCR ligands via nanobody tethering","volume":"15","author":"Sachdev","year":"2024","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib90","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1021\/acs.molpharmaceut.9b00360","article-title":"Nanobody-targeted photodynamic therapy Selectively Kills Viral GPCR-expressing glioblastoma cells","volume":"16","author":"De Groof","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.pharmr.2026.100160_bib91","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.74101","article-title":"Effector membrane translocation biosensors reveal G protein and \u03b2arrestin coupling profiles of 100 therapeutically relevant GPCRs","volume":"11","author":"Avet","year":"2022","journal-title":"Elife"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib92","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.cell.2019.04.044","article-title":"Illuminating G-protein-coupling selectivity of GPCRs","volume":"177","author":"Inoue","year":"2019","journal-title":"Cell"},{"issue":"8092","key":"10.1016\/j.pharmr.2026.100160_bib93","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-025-09643-2","article-title":"Designing allosteric modulators to change GPCR G protein subtype selectivity","volume":"648","author":"Moore","year":"2025","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113173","article-title":"Rules and mechanisms governing G protein coupling selectivity of GPCRs","volume":"42","author":"Masuho","year":"2023","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0283477","article-title":"Loss of biased signaling at a G protein-coupled receptor in overexpressed systems","volume":"18","author":"Li","year":"2023","journal-title":"PLoS One"},{"issue":"7835","key":"10.1016\/j.pharmr.2026.100160_bib96","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41586-020-2888-2","article-title":"Combinatorial expression of GPCR isoforms affects signalling and drug responses","volume":"587","author":"Marti-Solano","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib97","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.116.105502","article-title":"CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways","volume":"90","author":"Berchiche","year":"2016","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib98","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1124\/mol.117.108522","article-title":"C-X-C motif chemokine receptor 3 splice variants differentially activate beta-arrestins to regulate downstream signaling pathways","volume":"92","author":"Smith","year":"2017","journal-title":"Mol Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib99","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2007-07-102103","article-title":"CXCR4 dimerization and beta-arrestin-mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome","volume":"112","author":"Lagane","year":"2008","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100160_bib100","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1073\/pnas.0307601101","article-title":"A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia","volume":"101","author":"Gomes","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"29","key":"10.1016\/j.pharmr.2026.100160_bib101","doi-asserted-by":"crossref","first-page":"12072","DOI":"10.1073\/pnas.1222044110","article-title":"Identification of a \u03bc-\u03b4 opioid receptor heteromer-biased agonist with antinociceptive activity","volume":"110","author":"Gomes","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib102","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1111\/bph.70285","article-title":"Divergence in \u03bc and \u03b4 opioid receptor pharmacology in neurons and antinociceptive efficacy in neuropathic pain: insights from MP135 and CYM51010","volume":"183","author":"Inquimbert","year":"2026","journal-title":"Br J Pharmacol"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100160_bib103","doi-asserted-by":"crossref","first-page":"13618","DOI":"10.1021\/acs.jmedchem.0c00901","article-title":"Synthesis and pharmacology of a novel \u03bc-\u03b4 opioid receptor heteromer-selective agonist based on the carfentanyl template","volume":"63","author":"Faouzi","year":"2020","journal-title":"J Med Chem"},{"issue":"6800","key":"10.1016\/j.pharmr.2026.100160_bib104","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/35024095","article-title":"AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration","volume":"407","author":"AbdAlla","year":"2000","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100160_bib105","doi-asserted-by":"crossref","first-page":"18872","DOI":"10.1074\/jbc.M113.472381","article-title":"The arrestin-selective angiotensin AT1 receptor agonist (Sar 1, Ile4,Ile8)-AngII negatively regulates bradykinin B2 receptor signaling via AT1-B2 receptor heterodimers","volume":"288","author":"Wilson","year":"2013","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib106","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1074\/jbc.M804607200","article-title":"Lack of evidence for AT1R\/B2R heterodimerization in COS-7, HEK293, and NIH3T3 cells: how common is the AT1R\/B2R heterodimer?","volume":"284","author":"Hansen","year":"2009","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib107","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev-pharmtox-010814-124803","article-title":"DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility","volume":"55","author":"Urban","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib108","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nmeth.1232","article-title":"Engineering GPCR signaling pathways with RASSLs","volume":"5","author":"Conklin","year":"2008","journal-title":"Nat Methods"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100160_bib109","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1074\/jbc.M115.702282","article-title":"A G protein-biased designer G protein-coupled receptor useful for studying the physiological relevance of Gq\/11-dependent signaling pathways","volume":"291","author":"Hu","year":"2016","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib110","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1124\/mol.112.080358","article-title":"Design and functional characterization of a novel, arrestin-biased designer G protein-coupled receptor","volume":"82","author":"Nakajima","year":"2012","journal-title":"Mol Pharmacol"},{"issue":"50","key":"10.1016\/j.pharmr.2026.100160_bib111","doi-asserted-by":"crossref","first-page":"E8178","DOI":"10.1073\/pnas.1614347113","article-title":"Distinct cortical and striatal actions of a beta-arrestin-biased dopamine D2 receptor ligand reveal unique antipsychotic-like properties","volume":"113","author":"Urs","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib112","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.91861","article-title":"Phosphorylation bar-coding of free fatty acid receptor 2 is generated in a tissue-specific manner","volume":"12","author":"Barki","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.pharmr.2026.100160_bib113","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2019.05.006","article-title":"Biased signaling of G protein coupled receptors (GPCRs): molecular determinants of GPCR\/transducer selectivity and therapeutic potential","volume":"200","author":"Seyedabadi","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmr.2026.100160_bib114","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.62552","article-title":"\u03b2-arrestin 2 germline knockout does not attenuate opioid respiratory depression","volume":"10","author":"Bachmutsky","year":"2021","journal-title":"Elife"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib115","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"issue":"549","key":"10.1016\/j.pharmr.2026.100160_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat7650","article-title":"Manifold roles of beta-arrestins in GPCR signaling elucidated with siRNA and CRISPR\/Cas9","volume":"11","author":"Luttrell","year":"2018","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib117","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41467-017-02661-3","article-title":"Lack of beta-arrestin signaling in the absence of active G proteins","volume":"9","author":"Grundmann","year":"2018","journal-title":"Nat Commun"},{"issue":"42","key":"10.1016\/j.pharmr.2026.100160_bib118","doi-asserted-by":"crossref","first-page":"16657","DOI":"10.1073\/pnas.0707936104","article-title":"A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling","volume":"104","author":"Wisler","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib119","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1038\/s41467-022-34765-w","article-title":"How Carvedilol activates \u03b22-adrenoceptors","volume":"13","author":"Benkel","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib120","doi-asserted-by":"crossref","first-page":"7866","DOI":"10.1038\/s41467-023-42848-5","article-title":"How carvedilol does not activate \u03b22-adrenoceptors","volume":"14","author":"Lefkowitz","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib121","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.cell.2017.10.035","article-title":"Bias factor and therapeutic window correlate to predict safer opioid analgesics","volume":"171","author":"Schmid","year":"2017","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib122","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"DeWire","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"625","key":"10.1016\/j.pharmr.2026.100160_bib123","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci Signal"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib124","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.tips.2020.09.009","article-title":"Critical assessment of G protein-biased agonism at the \u03bc-opioid receptor","volume":"41","author":"Gillis","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib125","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","article-title":"Biased agonism: lessons from studies of opioid receptor agonists","volume":"63","author":"Kelly","year":"2023","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmr.2026.100160_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109906","article-title":"Signaling diversity of mu- and delta- opioid receptor ligands: re-evaluating the benefits of \u03b2-arrestin\/G protein signaling bias","volume":"80","author":"Pineyro","year":"2021","journal-title":"Cell Signal"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib127","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/nchembio.1665","article-title":"Spatial encoding of cyclic AMP signaling specificity by GPCR endocytosis","volume":"10","author":"Tsvetanova","year":"2014","journal-title":"Nat Chem Biol"},{"issue":"43","key":"10.1016\/j.pharmr.2026.100160_bib128","doi-asserted-by":"crossref","first-page":"27005","DOI":"10.1074\/jbc.272.43.27005","article-title":"A central role for beta-arrestins and clathrin-coated vesicle-mediated endocytosis in beta2-adrenergic receptor resensitization. Differential regulation of receptor resensitization in two distinct cell types","volume":"272","author":"Zhang","year":"1997","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib129","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1074\/jbc.273.2.685","article-title":"Essential role for G protein-coupled receptor endocytosis in the activation of mitogen-activated protein kinase","volume":"273","author":"Daaka","year":"1998","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib130","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nchembio.206","article-title":"Sustained cyclic AMP production by parathyroid hormone receptor endocytosis","volume":"5","author":"Ferrandon","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000172","article-title":"Persistent cAMP-signals triggered by internalized G-protein-coupled receptors","volume":"7","author":"Calebiro","year":"2009","journal-title":"PLoS Biol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib132","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.173","article-title":"Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors","volume":"5","author":"Mullershausen","year":"2009","journal-title":"Nat Chem Biol"},{"issue":"7442","key":"10.1016\/j.pharmr.2026.100160_bib133","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nature12000","article-title":"Conformational biosensors reveal GPCR signalling from endosomes","volume":"495","author":"Irannejad","year":"2013","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib134","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nchembio.2389","article-title":"Functional selectivity of GPCR-directed drug action through location bias","volume":"13","author":"Irannejad","year":"2017","journal-title":"Nat Chem Biol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib135","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1074\/jbc.M111.301366","article-title":"Activation of intracellular metabotropic glutamate receptor 5 in striatal neurons leads to up-regulation of genes associated with sustained synaptic transmission including Arc\/Arg3.1 protein","volume":"287","author":"Kumar","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100160_bib136","series-title":"Pharmacology of GPCRs Biased Signaling and Agonists","first-page":"65","article-title":"Structure-encoded location biased signaling in a Class B GPCR: focus on the PTH Type 1 receptor","volume":"290","author":"Pe\u00f1a","year":"2026"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib137","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/s41565-019-0568-x","article-title":"A pH-responsive nanoparticle targets the neurokinin 1 receptor in endosomes to prevent chronic pain","volume":"14","author":"Ram\u00edrez-Garc\u00eda","year":"2019","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib138","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1038\/s41467-022-33569-2","article-title":"Location bias contributes to functionally selective responses of biased CXCR3 agonists","volume":"13","author":"Eiger","year":"2022","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib139","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2414738122","article-title":"Extensive location bias of the GPCR-dependent translatome via site-selective activation of mTOR","volume":"122","author":"Klauer","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib140","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.cels.2021.02.001","article-title":"Diversity of the G\u03b2\u03b3 complexes defines spatial and temporal bias of GPCR signaling","volume":"12","author":"Masuho","year":"2021","journal-title":"Cell Syst"},{"key":"10.1016\/j.pharmr.2026.100160_bib141","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.48167","article-title":"Golgi localized beta1-adrenergic receptors stimulate Golgi PI4P hydrolysis by PLCepsilon to regulate cardiac hypertrophy","volume":"8","author":"Nash","year":"2019","journal-title":"Elife"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100160_bib142","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2220979120","article-title":"Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief","volume":"120","author":"Hegron","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"issue":"41","key":"10.1016\/j.pharmr.2026.100160_bib143","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2412687122","article-title":"Nanomedicines targeting protease-activated receptor 2 in endosomes provide sustained analgesia","volume":"122","author":"Teng","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib144","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10842","article-title":"The role of kinetic context in apparent biased agonism at GPCRs","volume":"7","author":"Klein Herenbrink","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib145","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67844-3","article-title":"Analyzing kinetic signaling data for G-protein-coupled receptors","volume":"10","author":"Hoare","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib146","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/s41467-019-09204-y","article-title":"Distinct G protein-coupled receptor phosphorylation motifs modulate arrestin affinity and activation and global conformation","volume":"10","author":"Mayer","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib147","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1016\/j.cell.2020.11.014","article-title":"How GPCR phosphorylation patterns orchestrate arrestin-mediated signaling","volume":"183","author":"Latorraca","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2026.100160_bib148","article-title":"Angiotensin receptor conformations stabilized by biased ligands differentially modulate \u03b2-arrestin interactions","volume":"2025","author":"Elgeti","year":"2025","journal-title":"bioRxiv"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib149","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1038\/s41589-025-01957-6","article-title":"Insights into G-protein coupling preference from cryo-EM structures of Gq-bound PTH1R","volume":"21","author":"Sano","year":"2025","journal-title":"Nat Chem Biol"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100160_bib150","doi-asserted-by":"crossref","first-page":"9649","DOI":"10.1073\/pnas.0904361106","article-title":"Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands","volume":"106","author":"Zidar","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib151","article-title":"Ligand-dependent mechanisms of CC chemokine Receptor 5 (CCR5) trafficking revealed by APEX2 proximity labeling proteomics","author":"Gu","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.pharmr.2026.100160_bib152","article-title":"ACKR3 Proximity labeling identifies novel G protein- and \u03b2-arrestin-independent GPCR interacting proteins","author":"Hicks","year":"2024","journal-title":"bioRxiv"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib153","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41589-024-01588-3","article-title":"Profiling the proximal proteome of the activated \u03bc-opioid receptor","volume":"20","author":"Polacco","year":"2024","journal-title":"Nat Chem Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib154","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cell.2017.03.022","article-title":"An approach to spatiotemporally resolve protein interaction networks in living cells","volume":"169","author":"Lobingier","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib155","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.chembiol.2025.04.006","article-title":"Spatiotemporally resolved GPCR interactome uncovers unique mediators of receptor agonism","volume":"32","author":"Shchepinova","year":"2025","journal-title":"Cell Chem Biol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib156","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1124\/molpharm.120.000178","article-title":"Proteomic approaches to investigate regulated trafficking and signaling of G protein-coupled receptors","volume":"99","author":"von Zastrow","year":"2021","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib157","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.cell.2017.03.028","article-title":"Multidimensional tracking of GPCR signaling via peroxidase-catalyzed proximity labeling","volume":"169","author":"Paek","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2026.100160_bib158","first-page":"237","article-title":"Proximity labeling for investigating protein-protein interactions","volume":"169","author":"Pfeiffer","year":"2022"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib159","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1021\/acschembio.8b00919","article-title":"Directed evolution of split APEX2 peroxidase","volume":"14","author":"Han","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.pharmr.2026.100160_bib160","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cellsig.2017.09.013","article-title":"Elucidating structural and molecular mechanisms of beta-arrestin-biased agonism at GPCRs via MS-based proteomics","volume":"41","author":"Xiao","year":"2018","journal-title":"Cell Signal"},{"issue":"555","key":"10.1016\/j.pharmr.2026.100160_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaq1075","article-title":"Biased agonists of the chemokine receptor CXCR3 differentially control chemotaxis and inflammation","volume":"11","author":"Smith","year":"2018","journal-title":"Sci Signal"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100160_bib162","doi-asserted-by":"crossref","first-page":"14495","DOI":"10.1073\/pnas.94.26.14495","article-title":"Chemotaxis in a lymphocyte cell line transfected with C-C chemokine receptor 2B: evidence that directed migration is mediated by betagamma dimers released by activation of Galphai-coupled receptors","volume":"94","author":"Arai","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"43","key":"10.1016\/j.pharmr.2026.100160_bib163","doi-asserted-by":"crossref","first-page":"37222","DOI":"10.1074\/jbc.M111.294116","volume":"286","author":"Delgado-Mart\u00edn","year":"2011","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib164","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2006-04-014753","article-title":"Influence of ERK activation on decreased chemotaxis of mature human cord blood monocyte-derived dendritic cells to CCL19 and CXCL12","volume":"109","author":"Li","year":"2007","journal-title":"Blood"},{"issue":"484","key":"10.1016\/j.pharmr.2026.100160_bib165","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aal3395","article-title":"Genetic evidence that beta-arrestins are dispensable for the initiation of beta(2)-adrenergic receptor signaling to ERK","volume":"10","author":"O\u2019Hayre","year":"2017","journal-title":"Sci Signal"},{"issue":"53","key":"10.1016\/j.pharmr.2026.100160_bib166","doi-asserted-by":"crossref","first-page":"27147","DOI":"10.1074\/jbc.M116.754887","article-title":"Targeted elimination of G proteins and arrestins defines their specific contributions to both intensity and duration of G protein-coupled receptor signaling","volume":"291","author":"Alvarez-Curto","year":"2016","journal-title":"J Biol Chem"},{"issue":"7705","key":"10.1016\/j.pharmr.2026.100160_bib167","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41586-018-0079-1","article-title":"Catalytic activation of beta-arrestin by GPCRs","volume":"557","author":"Eichel","year":"2018","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib168","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.cell.2023.04.018","article-title":"Plasma membrane preassociation drives \u03b2-arrestin coupling to receptors and activation","volume":"186","author":"Grimes","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib169","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/mol.111.072801","article-title":"Quantifying ligand bias at seven-transmembrane receptors","volume":"80","author":"Rajagopal","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib170","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.tips.2011.01.002","article-title":"Analytical pharmacology: the impact of numbers on pharmacology","volume":"32","author":"Kenakin","year":"2011","journal-title":"Trends Pharmacol Sci"},{"issue":"4-6","key":"10.1016\/j.pharmr.2026.100160_bib171","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00210-008-0260-4","article-title":"On the analysis of ligand-directed signaling at G protein-coupled receptors","volume":"377","author":"Ehlert","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"7329","key":"10.1016\/j.pharmr.2026.100160_bib172","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature09648","article-title":"Structure of a nanobody-stabilized active state of the \u03b22 adrenoceptor","volume":"469","author":"Rasmussen","year":"2011","journal-title":"Nature"},{"issue":"7447","key":"10.1016\/j.pharmr.2026.100160_bib173","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nature12120","article-title":"Structure of active beta-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide","volume":"497","author":"Shukla","year":"2013","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100160_bib174","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1073\/pnas.1722336115","article-title":"Sortase ligation enables homogeneous GPCR phosphorylation to reveal diversity in beta-arrestin coupling","volume":"115","author":"Staus","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib175","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41422-025-01095-7","article-title":"Molecular mechanism of the arrestin-biased agonism of neurotensin receptor 1 by an intracellular allosteric modulator","volume":"35","author":"Sun","year":"2025","journal-title":"Cell Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib176","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.pharmthera.2005.09.008","article-title":"The structural basis of arrestin-mediated regulation of G-protein-coupled receptors","volume":"110","author":"Gurevich","year":"2006","journal-title":"Pharmacol Ther"},{"issue":"30","key":"10.1016\/j.pharmr.2026.100160_bib177","doi-asserted-by":"crossref","first-page":"21919","DOI":"10.1016\/S0021-9258(19)36700-6","article-title":"Cell-free expression of visual arrestin. Truncation mutagenesis identifies multiple domains involved in rhodopsin interaction","volume":"267","author":"Gurevich","year":"1992","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib178","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1038\/s41467-017-01218-8","article-title":"Structural basis of arrestin-3 activation and signaling","volume":"8","author":"Chen","year":"2017","journal-title":"Nat Commun"},{"issue":"36","key":"10.1016\/j.pharmr.2026.100160_bib179","doi-asserted-by":"crossref","first-page":"13218","DOI":"10.1074\/jbc.AC119.009848","article-title":"Detergent- and phospholipid-based reconstitution systems have differential effects on constitutive activity of G-protein-coupled receptors","volume":"294","author":"Staus","year":"2019","journal-title":"J Biol Chem"},{"issue":"7513","key":"10.1016\/j.pharmr.2026.100160_bib180","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nature13430","article-title":"Visualization of arrestin recruitment by a G-protein-coupled receptor","volume":"512","author":"Shukla","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib181","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.str.2024.05.014","article-title":"Roles of the gate loop in beta-arrestin-1 conformational dynamics and phosphorylated receptor interaction","volume":"32","author":"Kim","year":"2024","journal-title":"Structure"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib182","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/s42003-025-08649-w","article-title":"Molecular mechanism of beta-arrestin 2 interaction with phosphorylated intracellular loop 3 of dopamine receptor D2","volume":"8","author":"Kim","year":"2025","journal-title":"Commun Biol"},{"issue":"7212","key":"10.1016\/j.pharmr.2026.100160_bib183","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nature07330","article-title":"Crystal structure of opsin in its G-protein-interacting conformation","volume":"455","author":"Scheerer","year":"2008","journal-title":"Nature"},{"issue":"7626","key":"10.1016\/j.pharmr.2026.100160_bib184","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nature19803","article-title":"Erratum: structure of the adenosine A2A receptor bound to an engineered G protein","volume":"538","author":"Carpenter","year":"2016","journal-title":"Nature"},{"issue":"6440","key":"10.1016\/j.pharmr.2026.100160_bib185","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1126\/science.aaw5188","article-title":"Structures of the M1 and M2 muscarinic acetylcholine receptor\/G-protein complexes","volume":"364","author":"Maeda","year":"2019","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib186","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cell.2021.01.027","article-title":"Structural insights into the human D1 and D2 dopamine receptor signaling complexes","volume":"184","author":"Zhuang","year":"2021","journal-title":"Cell"},{"issue":"6484","key":"10.1016\/j.pharmr.2026.100160_bib187","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.aaz5346","article-title":"Structural basis of G(s) and G(i) recognition by the human glucagon receptor","volume":"367","author":"Qiao","year":"2020","journal-title":"Science"},{"issue":"7478","key":"10.1016\/j.pharmr.2026.100160_bib188","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12735","article-title":"Activation and allosteric modulation of a muscarinic acetylcholine receptor","volume":"504","author":"Kruse","year":"2013","journal-title":"Nature"},{"issue":"7657","key":"10.1016\/j.pharmr.2026.100160_bib189","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature22394","article-title":"Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"issue":"7711","key":"10.1016\/j.pharmr.2026.100160_bib190","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41586-018-0241-9","article-title":"Cryo-EM structure of the serotonin 5-HT1B receptor coupled to heterotrimeric Go","volume":"558","author":"Garc\u00eda-Nafr\u00eda","year":"2018","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib191","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.cell.2018.11.040","article-title":"Structure of a signaling cannabinoid receptor 1-G protein complex","volume":"176","author":"Krishna Kumar","year":"2019","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib192","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2020.01.008","article-title":"Activation and signaling mechanism revealed by cannabinoid receptor-Gi complex structures","volume":"180","author":"Hua","year":"2020","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100160_bib193","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/s41422-021-00569-8","article-title":"Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-alpha-MSH and setmelanotide","volume":"31","author":"Heyder","year":"2021","journal-title":"Cell Res"},{"issue":"7711","key":"10.1016\/j.pharmr.2026.100160_bib194","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the micro-opioid receptor-G(i) protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.pharmr.2026.100160_bib195","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1021\/acs.biochem.7b00747","article-title":"Structural basis for G protein-coupled receptor activation","volume":"56","author":"Manglik","year":"2017","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib196","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1146\/annurev-biochem-060614-033910","article-title":"The molecular basis of G protein-coupled receptor activation","volume":"87","author":"Weis","year":"2018","journal-title":"Annu Rev Biochem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib197","doi-asserted-by":"crossref","first-page":"6670","DOI":"10.1038\/s41467-022-33851-3","article-title":"Structure insights into selective coupling of G protein subtypes by a class B G protein-coupled receptor","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat Commun"},{"issue":"7654","key":"10.1016\/j.pharmr.2026.100160_bib198","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature22070","article-title":"Selectivity determinants of GPCR-G-protein binding","volume":"545","author":"Flock","year":"2017","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib199","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.jmb.2009.09.010","article-title":"Kinetic advantage of intrinsically disordered proteins in coupled folding-binding process: a critical assessment of the \u201cfly-casting\u201d mechanism","volume":"393","author":"Huang","year":"2009","journal-title":"J Mol Biol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib200","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3390\/biom13101552","article-title":"G protein-coupled receptor kinase 2 selectively enhances beta-arrestin Recruitment to the D2 dopamine receptor through mechanisms that are independent of receptor phosphorylation","volume":"13","author":"S\u00e1nchez-Soto","year":"2023","journal-title":"Biomolecules"},{"issue":"5326","key":"10.1016\/j.pharmr.2026.100160_bib201","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1126\/science.277.5326.687","article-title":"A G protein-coupled receptor phosphatase required for rhodopsin function","volume":"277","author":"Vin\u00f3s","year":"1997","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib202","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1471-4159.2006.04364.x","article-title":"Purification of visual arrestin from squid photoreceptors and characterization of arrestin interaction with rhodopsin and rhodopsin kinase","volume":"101","author":"Swardfager","year":"2007","journal-title":"J Neurochem"},{"issue":"7447","key":"10.1016\/j.pharmr.2026.100160_bib203","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/nature12133","article-title":"Crystal structure of pre-activated arrestin p44","volume":"497","author":"Kim","year":"2013","journal-title":"Nature"},{"issue":"24","key":"10.1016\/j.pharmr.2026.100160_bib204","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.cell.2022.10.018","article-title":"Membrane phosphoinositides regulate GPCR-\u03b2-arrestin complex assembly and dynamics","volume":"185","author":"Janetzko","year":"2022","journal-title":"Cell"},{"issue":"7562","key":"10.1016\/j.pharmr.2026.100160_bib205","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature14656","article-title":"Crystal structure of rhodopsin bound to arrestin by femtosecond X-ray laser","volume":"523","author":"Kang","year":"2015","journal-title":"Nature"},{"issue":"7868","key":"10.1016\/j.pharmr.2026.100160_bib206","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-021-03721-x","article-title":"Structures of rhodopsin in complex with G-protein-coupled receptor kinase 1","volume":"595","author":"Chen","year":"2021","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib207","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.cell.2017.07.002","article-title":"Identification of phosphorylation codes for arrestin recruitment by G protein-coupled receptors","volume":"170","author":"Zhou","year":"2017","journal-title":"Cell"},{"issue":"7818","key":"10.1016\/j.pharmr.2026.100160_bib208","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41586-020-2419-1","article-title":"Molecular basis of \u03b2-arrestin coupling to formoterol-bound \u03b21-adrenoceptor","volume":"583","author":"Lee","year":"2020","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100160_bib209","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1016\/j.neuron.2022.08.006","article-title":"Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD","volume":"110","author":"Cao","year":"2022","journal-title":"Neuron"},{"issue":"7798","key":"10.1016\/j.pharmr.2026.100160_bib210","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41586-020-1954-0","article-title":"Structure of the M2 muscarinic receptor-\u03b2-arrestin complex in a lipid nanodisc","volume":"579","author":"Staus","year":"2020","journal-title":"Nature"},{"issue":"7798","key":"10.1016\/j.pharmr.2026.100160_bib211","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41586-020-1953-1","article-title":"Structure of the neurotensin receptor 1 in complex with beta-arrestin 1","volume":"579","author":"Huang","year":"2020","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.pharmr.2026.100160_bib212","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abo7761","article-title":"Structure of the vasopressin hormone-V2 receptor-beta-arrestin1 ternary complex","volume":"8","author":"Bous","year":"2022","journal-title":"Sci Adv"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100160_bib213","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1016\/j.cell.2023.11.017","article-title":"Snapshot of the cannabinoid receptor 1-arrestin complex unravels the biased signaling mechanism","volume":"186","author":"Liao","year":"2023","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib214","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41422-019-0256-2","article-title":"A complex structure of arrestin-2 bound to a G protein-coupled receptor","volume":"29","author":"Yin","year":"2019","journal-title":"Cell Res"},{"issue":"8070","key":"10.1016\/j.pharmr.2026.100160_bib215","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41586-025-09024-9","article-title":"Effect of phosphorylation barcodes on arrestin binding to a chemokine receptor","volume":"643","author":"Chen","year":"2025","journal-title":"Nature"},{"issue":"6775","key":"10.1016\/j.pharmr.2026.100160_bib216","doi-asserted-by":"crossref","DOI":"10.1126\/science.adt8794","article-title":"Noncanonical agonist-dependent and -independent arrestin recruitment of GPR1","volume":"390","author":"Cai","year":"2025","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib217","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/s41594-019-0330-y","article-title":"Structure of an endosomal signaling G protein-coupled receptor-G protein-\u03b2-arrestin megacomplex","volume":"26","author":"Nguyen","year":"2019","journal-title":"Nat Struct Mol Biol"},{"issue":"6534","key":"10.1016\/j.pharmr.2026.100160_bib218","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay1833","article-title":"Noncanonical scaffolding of G\u03b1i and \u03b2-arrestin by G protein-coupled receptors","volume":"371","author":"Smith","year":"2021","journal-title":"Science"},{"issue":"726","key":"10.1016\/j.pharmr.2026.100160_bib219","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abg5203","article-title":"Biased agonists of the chemokine receptor CXCR3 differentially signal through G\u03b1i:\u03b2-arrestin complexes","volume":"15","author":"Zheng","year":"2022","journal-title":"Sci Signal"},{"key":"10.1016\/j.pharmr.2026.100160_bib220","article-title":"Beta-arrestin recruitment facilitates a direct association with G proteins","volume":"2025","author":"Lee","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.pharmr.2026.100160_bib221","article-title":"Follicle-stimulating hormone induces lipid droplets via G\u03b1i\/o and \u03b2-arrestin in an endometrial cancer cell line","volume":"12","author":"Sayers","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib222","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/s41467-026-68690-z","article-title":"Functional and structural insights into interactions between \u03b2-Arrestin 1 and G\u03b1s or G\u03b1i1","volume":"17","author":"Duan","year":"2026","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib223","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1146\/annurev.biochem.67.1.653","article-title":"G protein-coupled receptor kinases","volume":"67","author":"Pitcher","year":"1998","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmr.2026.100160_bib224","first-page":"319","article-title":"Desensitization of G protein-coupled receptors","volume":"51","author":"Freedman","year":"1996","journal-title":"Recent Prog Horm Res"},{"issue":"36","key":"10.1016\/j.pharmr.2026.100160_bib225","doi-asserted-by":"crossref","first-page":"25262","DOI":"10.1074\/jbc.M114.593178","article-title":"Mapping the putative G protein-coupled receptor (GPCR) docking site on GPCR kinase 2: insights from intact cell phosphorylation and recruitment assays","volume":"289","author":"Beautrait","year":"2014","journal-title":"J Biol Chem"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100160_bib226","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1038\/emboj.2010.206","article-title":"Molecular basis for activation of G protein-coupled receptor kinases","volume":"29","author":"Boguth","year":"2010","journal-title":"EMBO J"},{"issue":"48","key":"10.1016\/j.pharmr.2026.100160_bib227","doi-asserted-by":"crossref","first-page":"47466","DOI":"10.1074\/jbc.M308257200","article-title":"Development of a yeast bioassay to characterize G protein-coupled receptor kinases. Identification of an NH2-terminal region essential for receptor phosphorylation","volume":"278","author":"Noble","year":"2003","journal-title":"J Biol Chem"},{"issue":"7974","key":"10.1016\/j.pharmr.2026.100160_bib228","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-023-06395-9","article-title":"GPCR activation and GRK2 assembly by a biased intracellular agonist","volume":"620","author":"Duan","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib229","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.cell.2017.03.047","article-title":"Structural and functional analysis of a \u03b22-adrenergic receptor complex with GRK5","volume":"169","author":"Komolov","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib230","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41467-022-28056-7","article-title":"Heterotrimeric Gq proteins act as a switch for GRK5\/6 selectivity underlying beta-arrestin transducer bias","volume":"13","author":"Kawakami","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib231","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41467-022-28152-8","article-title":"GPCR kinase knockout cells reveal the impact of individual GRKs on arrestin binding and GPCR regulation","volume":"13","author":"Drube","year":"2022","journal-title":"Nat Commun"},{"issue":"52","key":"10.1016\/j.pharmr.2026.100160_bib232","doi-asserted-by":"crossref","first-page":"41049","DOI":"10.1074\/jbc.M007159200","article-title":"An additional phosphate-binding element in arrestin molecule. Implications for the mechanism of arrestin activation","volume":"275","author":"Vishnivetskiy","year":"2000","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100160_bib233","doi-asserted-by":"crossref","first-page":"17201","DOI":"10.1074\/jbc.M910348199","article-title":"Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors","volume":"275","author":"Oakley","year":"2000","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib234","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.molcel.2023.04.025","article-title":"Structural snapshots uncover a key phosphorylation motif in GPCRs driving beta-arrestin activation","volume":"83","author":"Maharana","year":"2023","journal-title":"Mol Cell"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib235","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.molcel.2023.05.002","article-title":"A key GPCR phosphorylation motif discovered in arrestin2\u22c5CCR5 phosphopeptide complexes","volume":"83","author":"Isaikina","year":"2023","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib236","doi-asserted-by":"crossref","first-page":"8202","DOI":"10.1038\/ncomms9202","article-title":"Phospho-selective mechanisms of arrestin conformations and functions revealed by unnatural amino acid incorporation and (19)F-NMR","volume":"6","author":"Yang","year":"2015","journal-title":"Nat Commun"},{"issue":"28","key":"10.1016\/j.pharmr.2026.100160_bib237","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1021\/acs.biochem.5b00285","article-title":"G protein-coupled receptor kinase 2 (GRK2) and 5 (GRK5) exhibit selective phosphorylation of the neurotensin receptor in vitro","volume":"54","author":"Inagaki","year":"2015","journal-title":"Biochemistry"},{"issue":"suppl 1","key":"10.1016\/j.pharmr.2026.100160_bib238","first-page":"S167","article-title":"G-protein-coupled receptor phosphorylation: where, when and by whom","volume":"153","author":"Tobin","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100160_bib239","doi-asserted-by":"crossref","first-page":"11506","DOI":"10.1074\/jbc.M110.154526","article-title":"Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code","volume":"286","author":"Butcher","year":"2011","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib240","doi-asserted-by":"crossref","first-page":"7805","DOI":"10.1074\/jbc.M109.091173","article-title":"Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling","volume":"285","author":"Busillo","year":"2010","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib241","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.chembiol.2023.03.006","article-title":"Phosphorylation barcodes direct biased chemokine signaling at CXCR3","volume":"30","author":"Eiger","year":"2023","journal-title":"Cell Chem Biol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib242","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nchembio.2126","article-title":"Conformationally selective RNA aptamers allosterically modulate the beta2-adrenoceptor","volume":"12","author":"Kahsai","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib243","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.cell.2013.01.008","article-title":"The dynamic process of beta(2)-adrenergic receptor activation. Cell","volume":"152","author":"Nygaard","year":"2013","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib244","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.cell.2015.04.043","article-title":"Structural Insights into the dynamic process of \u03b22-adrenergic receptor signaling","volume":"161","author":"Manglik","year":"2015","journal-title":"Cell"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100160_bib245","doi-asserted-by":"crossref","first-page":"8304","DOI":"10.1073\/pnas.1119881109","article-title":"Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor","volume":"109","author":"Mary","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6132","key":"10.1016\/j.pharmr.2026.100160_bib246","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1126\/science.1232808","article-title":"Structural features for functional selectivity at serotonin receptors","volume":"340","author":"Wacker","year":"2013","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100160_bib247","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022112940","article-title":"Structural insights into angiotensin receptor signaling modulation by balanced and biased agonists","volume":"42","author":"Zhang","year":"2023","journal-title":"EMBO J"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100160_bib248","doi-asserted-by":"crossref","first-page":"15835","DOI":"10.1074\/jbc.M114.627356","article-title":"Identification of distinct conformations of the angiotensin-II type 1 receptor associated with the Gq\/11 protein pathway and the \u03b2-arrestin pathway using molecular dynamics simulations","volume":"290","author":"Cabana","year":"2015","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib249","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.cell.2018.12.006","article-title":"Distinctive activation mechanism for angiotensin receptor revealed by a synthetic nanobody","volume":"176","author":"Wingler","year":"2019","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib250","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1038\/s41467-021-25020-9","article-title":"Activation pathway of a G protein-coupled receptor uncovers conformational intermediates as targets for allosteric drug design","volume":"12","author":"Lu","year":"2021","journal-title":"Nat Commun"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100160_bib251","doi-asserted-by":"crossref","first-page":"17409","DOI":"10.1074\/jbc.RA119.010324","article-title":"Genetic code expansion and photocross-linking identify different beta-arrestin binding modes to the angiotensin II type 1 receptor","volume":"294","author":"Gagnon","year":"2019","journal-title":"J Biol Chem"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100160_bib252","doi-asserted-by":"crossref","first-page":"4636","DOI":"10.3390\/molecules25204636","article-title":"Molecular Modeling of micro opioid receptor ligands with various functional properties: PZM21, SR-17018, morphine, and fentanyl-simulated interaction patterns confronted with experimental data","volume":"25","author":"Podlewska","year":"2020","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib253","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41386-019-0491-8","article-title":"A G protein signaling-biased agonist at the \u03bc-opioid receptor reverses morphine tolerance while preventing morphine withdrawal","volume":"45","author":"Grim","year":"2020","journal-title":"Neuropsychopharmacology"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100160_bib254","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1016\/j.cell.2022.09.041","article-title":"Molecular recognition of morphine and fentanyl by the human \u03bc-opioid receptor","volume":"185","author":"Zhuang","year":"2022","journal-title":"Cell"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100160_bib255","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1021\/acs.biochem.6b00948","article-title":"How oliceridine (TRV-130) binds and stabilizes a \u03bc-opioid receptor conformational state that selectively triggers G protein signaling pathways","volume":"55","author":"Schneider","year":"2016","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib256","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41589-022-01208-y","article-title":"Insights into distinct signaling profiles of the \u03bcOR activated by diverse agonists","volume":"19","author":"Qu","year":"2023","journal-title":"Nat Chem Biol"},{"issue":"8011","key":"10.1016\/j.pharmr.2026.100160_bib257","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-07295-2","article-title":"Ligand efficacy modulates conformational dynamics of the \u03bc-opioid receptor","volume":"629","author":"Zhao","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib258","doi-asserted-by":"crossref","first-page":"9392","DOI":"10.1038\/s41467-025-64882-1","article-title":"Structural and dynamic insights into the biased signaling mechanism of the human kappa Opioid receptor","volume":"16","author":"Suno-Ikeda","year":"2025","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib259","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/pr.118.016790","article-title":"Biased receptor signaling in drug discovery","volume":"71","author":"Kenakin","year":"2019","journal-title":"Pharmacol Rev"},{"issue":"5449","key":"10.1016\/j.pharmr.2026.100160_bib260","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1126\/science.286.5449.2495","article-title":"Enhanced morphine analgesia in mice lacking beta-arrestin 2","volume":"286","author":"Bohn","year":"1999","journal-title":"Science"},{"issue":"6813","key":"10.1016\/j.pharmr.2026.100160_bib261","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/35047086","article-title":"Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence","volume":"408","author":"Bohn","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib262","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42003-024-06571-1","article-title":"Key phosphorylation sites for robust beta-arrestin2 binding at the MOR revisited","volume":"7","author":"Underwood","year":"2024","journal-title":"Commun Biol"},{"issue":"539","key":"10.1016\/j.pharmr.2026.100160_bib263","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aas9609","article-title":"Multisite phosphorylation is required for sustained interaction with GRKs and arrestins during rapid \u03bc-opioid receptor desensitization","volume":"11","author":"Miess","year":"2018","journal-title":"Sci Signal"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib264","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/bph.15334","article-title":"A novel G protein-biased agonist at the \u03bc opioid receptor induces substantial receptor desensitisation through G protein-coupled receptor kinase","volume":"180","author":"Groom","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib265","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1476-5381.2011.01382.x","article-title":"Agonist-selective patterns of \u03bc-opioid receptor phosphorylation revealed by phosphosite-specific antibodies","volume":"164","author":"Doll","year":"2011","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib266","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0006-8993(01)02179-5","article-title":"Agonist-induced Mu Opioid receptor phosphorylation and functional desensitization in rat thalamus","volume":"898","author":"Deng","year":"2001","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib267","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1124\/mol.112.082875","article-title":"Differentiation of opioid drug effects by hierarchical multi-site phosphorylation","volume":"83","author":"Just","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"13","key":"10.1016\/j.pharmr.2026.100160_bib268","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of beta-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib269","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/s41467-018-08162-1","article-title":"Phosphorylation-deficient G-protein-biased \u03bc-opioid receptors improve analgesia and diminish tolerance but worsen opioid side effects","volume":"10","author":"Kliewer","year":"2019","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib270","doi-asserted-by":"crossref","first-page":"e473","DOI":"10.1016\/j.bja.2020.09.021","article-title":"Approval of oliceridine (TRV130) for intravenous use in moderate to severe pain in adults","volume":"125","author":"Lambert","year":"2020","journal-title":"Br J Anaesth"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib271","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s00213-024-06690-x","article-title":"Comparison of the reinforcing, antinociceptive, and respiratory depressant effects of prototypical and G-protein-biased mu-opioid receptor agonists in male and female Sprague-Dawley rats","volume":"241","author":"Zamarripa","year":"2024","journal-title":"Psychopharmacol (Berl)"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib272","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/nm0496-412","article-title":"Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure","volume":"2","author":"Paxton","year":"1996","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100160_bib273","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1038\/nm1196-1240","article-title":"The role of a mutant CCR5 allele in HIV-1 transmission and disease progression","volume":"2","author":"Huang","year":"1996","journal-title":"Nat Med"},{"issue":"5283","key":"10.1016\/j.pharmr.2026.100160_bib274","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1126\/science.273.5283.1856","volume":"273","author":"Dean","year":"1996","journal-title":"Science"},{"issue":"6593","key":"10.1016\/j.pharmr.2026.100160_bib275","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/382722a0","article-title":"Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene","volume":"382","author":"Samson","year":"1996","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib276","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0092-8674(00)80110-5","article-title":"Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection","volume":"86","author":"Liu","year":"1996","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib277","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.tips.2007.06.006","article-title":"Beta-arrestin-biased ligands at seven-transmembrane receptors","volume":"28","author":"Violin","year":"2007","journal-title":"Trends Pharmacol Sci"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib278","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCHEARTFAILURE.111.962571","article-title":"Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure","volume":"4","author":"Boerrigter","year":"2011","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib279","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1124\/jpet.110.173005","article-title":"Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance","volume":"335","author":"Violin","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"19","key":"10.1016\/j.pharmr.2026.100160_bib280","doi-asserted-by":"crossref","first-page":"E2517","DOI":"10.1073\/pnas.1502740112","article-title":"Targeting beta-arrestin2 in the treatment of L-dopa-induced dyskinesia in Parkinson disease","volume":"112","author":"Urs","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib281","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.coph.2014.03.007","article-title":"Role for beta-arrestin in mediating paradoxical beta2AR and PAR2 signaling in asthma","volume":"16","author":"Walker","year":"2014","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib282","doi-asserted-by":"crossref","first-page":"6976","DOI":"10.1074\/jbc.273.12.6976","article-title":"Role of clathrin-mediated endocytosis in agonist-induced down-regulation of the beta2-adrenergic receptor","volume":"273","author":"Gagnon","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100160_bib283","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109905","article-title":"Biased agonism at beta-adrenergic receptors","volume":"80","author":"Ippolito","year":"2021","journal-title":"Cell Signal"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib284","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1165\/rcmb.2025-0144TR","article-title":"Biased orthosteric agonism and allosteric modulation: emerging strategies for developing new class of \u03b2-agonists for obstructive airway diseases","volume":"73","author":"Shah","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib285","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1152\/jn.00563.2012","article-title":"Pain-facilitating medullary neurons contribute to opioid-induced respiratory depression","volume":"108","author":"Phillips","year":"2012","journal-title":"J Neurophysiol"},{"issue":"552","key":"10.1016\/j.pharmr.2026.100160_bib286","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aat2214","article-title":"Biased antagonism of CXCR4 avoids antagonist tolerance","volume":"11","author":"Hitchinson","year":"2018","journal-title":"Sci Signal"},{"key":"10.1016\/j.pharmr.2026.100160_bib287","doi-asserted-by":"crossref","first-page":"8918","DOI":"10.1038\/ncomms9918","article-title":"Autocrine selection of a GLP-1R G-protein\u2013biased agonist with potent antidiabetic effects","volume":"6","author":"Zhang","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib288","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/bph.12420","article-title":"Engendering biased signalling from the calcium-sensing receptor for the pharmacotherapy of diverse disorders","volume":"171","author":"Leach","year":"2014","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib289","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1124\/jpet.112.197210","article-title":"Strontium is a biased agonist of the calcium-sensing receptor in rat medullary thyroid carcinoma 6-23 cells","volume":"343","author":"Thomsen","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib290","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1124\/jpet.110.178681","article-title":"Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion","volume":"337","author":"Henley","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100160_bib291","doi-asserted-by":"crossref","first-page":"14990","DOI":"10.1074\/jbc.M109.099689","article-title":"Expression of a G protein-coupled receptor (GPCR) leads to attenuation of signaling by other GPCRs: experimental evidence for a spontaneous GPCR constitutive inactive form","volume":"285","author":"Tubio","year":"2010","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib292","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1471-2164-12-14","article-title":"Expression of G protein-coupled receptors and related proteins in HEK293, AtT20, BV2, and N18 cell lines as revealed by microarray analysis","volume":"12","author":"Atwood","year":"2011","journal-title":"BMC Genomics"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib293","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/j.1476-5381.2011.01434.x","article-title":"GPCR expression in tissues and cells: are the optimal receptors being used as drug targets?","volume":"165","author":"Insel","year":"2012","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib294","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.cell.2008.08.040","article-title":"Anatomical profiling of G protein-coupled receptor expression","volume":"135","author":"Regard","year":"2008","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib295","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/bph.12222","article-title":"Efficacy and ligand bias at the \u03bc-opioid receptor","volume":"169","author":"Kelly","year":"2013","journal-title":"Br J Pharmacol"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100160_bib296","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/sj.emboj.7600334","article-title":"Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375","volume":"23","author":"Schulz","year":"2004","journal-title":"EMBO J"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib297","doi-asserted-by":"crossref","first-page":"7157","DOI":"10.1073\/pnas.95.12.7157","article-title":"Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness","volume":"95","author":"Zhang","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"32","key":"10.1016\/j.pharmr.2026.100160_bib298","doi-asserted-by":"crossref","first-page":"19021","DOI":"10.1074\/jbc.271.32.19021","article-title":"Morphine activates opioid receptors without causing their rapid internalization","volume":"271","author":"Keith","year":"1996","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib299","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.schres.2014.07.040","article-title":"Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia","volume":"159","author":"Funk","year":"2014","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib300","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41419-020-2596-8","article-title":"\u03b2-arrestin2 deficiency protects against hepatic fibrosis in mice and prevents synthesis of extracellular matrix","volume":"11","author":"Sun","year":"2020","journal-title":"Cell Death Dis"},{"issue":"18","key":"10.1016\/j.pharmr.2026.100160_bib301","doi-asserted-by":"crossref","first-page":"7395","DOI":"10.1073\/pnas.1221608110","article-title":"Deficiency of \u03b2-arrestin1 ameliorates collagen-induced arthritis with impaired TH17 cell differentiation","volume":"110","author":"Li","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib302","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/nan.12742","article-title":"G protein-coupled receptor kinases are associated with Alzheimer\u2019s disease pathology","volume":"47","author":"Guimar\u00e3es","year":"2021","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib303","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.neurobiolaging.2006.10.012","article-title":"Arrestins and two receptor kinases are upregulated in Parkinson\u2019s disease with dementia","volume":"29","author":"Bychkov","year":"2008","journal-title":"Neurobiol Aging"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib304","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.nbd.2004.10.005","article-title":"L-dopa reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain","volume":"18","author":"Bezard","year":"2005","journal-title":"Neurobiol Dis"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib305","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1096\/fj.07-9002com","article-title":"Glucocorticoids regulate innate immunity in a model of multiple sclerosis: reciprocal interactions between the A1 adenosine receptor and beta-arrestin-1 in monocytoid cells","volume":"22","author":"Tsutsui","year":"2008","journal-title":"FASEB J"},{"issue":"2 Pt 2","key":"10.1016\/j.pharmr.2026.100160_bib306","first-page":"H707","article-title":"Adenylyl cyclase and G protein receptor kinase expression during development of heart failure","volume":"273","author":"Ping","year":"1997","journal-title":"Am J Physiol"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib307","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0022-2828(03)00243-8","article-title":"The beta-adrenergic receptor kinase in heart failure","volume":"35","author":"Petrofski","year":"2003","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib308","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0735-1097(01)01396-1","article-title":"Regulation of myocardial betaARK1 expression in catecholamine-induced cardiac hypertrophy in transgenic mice overexpressing \u03b11B-adrenergic receptors","volume":"38","author":"Iaccarino","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib309","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1161\/01.CIR.87.2.454","article-title":"Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart","volume":"87","author":"Ungerer","year":"1993","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib310","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejphar.2004.03.015","article-title":"Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases","volume":"489","author":"Dzimiri","year":"2004","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib311","first-page":"3047","article-title":"G protein-coupled receptor kinases in normal and failing myocardium","volume":"16","author":"Huang","year":"2011","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100160_bib312","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1089\/ars.2014.5876","article-title":"GRK2 in the heart: a GPCR kinase and beyond","volume":"21","author":"Huang","year":"2014","journal-title":"Antioxid Redox Signal"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib313","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1161\/CIRCRESAHA.111.253260","article-title":"Gi-biased \u03b22AR signaling links GRK2 upregulation to heart failure","volume":"110","author":"Zhu","year":"2012","journal-title":"Circ Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib314","doi-asserted-by":"crossref","first-page":"7885","DOI":"10.1038\/s41598-017-07392-5","article-title":"G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning","volume":"7","author":"Onfroy","year":"2017","journal-title":"Sci Rep"},{"issue":"4535","key":"10.1016\/j.pharmr.2026.100160_bib315","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/178697b0","article-title":"Receptor occupancy and tissue response","volume":"178","author":"Nickerson","year":"1956","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib316","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0026-895X(25)13629-8","article-title":"Receptor reserve masks partial agonist activity of drugs in a cloned rat 5-hydroxytryptamine1B receptor expression system","volume":"43","author":"Adham","year":"1993","journal-title":"Mol Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib317","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/pro.3872","article-title":"A cellular perspective of bias at G protein-coupled receptors","volume":"29","author":"Fernandez","year":"2020","journal-title":"Protein Sci"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib318","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/s41467-018-03314-9","article-title":"Mechanistic insights into allosteric regulation of the A2A adenosine G protein-coupled receptor by physiological cations","volume":"9","author":"Ye","year":"2018","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib319","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nchembio.1960","article-title":"Allosteric regulation of G protein-coupled receptor activity by phospholipids","volume":"12","author":"Dawaliby","year":"2016","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib320","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1038\/s41467-019-10108-0","article-title":"Local membrane charge regulates \u03b22 adrenergic receptor coupling to Gi3","volume":"10","author":"Strohman","year":"2019","journal-title":"Nat Commun"},{"issue":"7714","key":"10.1016\/j.pharmr.2026.100160_bib321","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41586-018-0325-6","article-title":"PtdIns(4,5)P2 stabilizes active states of GPCRs and enhances selectivity of G-protein coupling","volume":"559","author":"Yen","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib322","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/pharmrev.120.000082","article-title":"Posttranslational modifications of G protein-coupled receptors control cellular signaling dynamics in space and time","volume":"73","author":"Patwardhan","year":"2021","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib323","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nchembio.2267","article-title":"\u03b22-adrenergic receptor control of endosomal PTH receptor signaling via G\u03b2\u03b3","volume":"13","author":"Jean-Alphonse","year":"2017","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.pharmr.2026.100160_bib324","series-title":"Transmembrane Signaling Protocols","first-page":"51","article-title":"Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases","volume":"332","author":"Natarajan","year":"2006"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib325","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.beem.2013.02.006","article-title":"Role of the calcium-sensing receptor in extracellular calcium homeostasis","volume":"27","author":"Brown","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib326","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.tips.2015.02.004","article-title":"Towards tissue-specific pharmacology: insights from the calcium-sensing receptor as a paradigm for GPCR (patho)physiological bias","volume":"36","author":"Leach","year":"2015","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib327","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ceca.2011.11.009","article-title":"Biased agonism of the calcium-sensing receptor","volume":"51","author":"Thomsen","year":"2012","journal-title":"Cell Calcium"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100160_bib328","doi-asserted-by":"crossref","first-page":"19452","DOI":"10.1074\/jbc.M101450200","article-title":"Molecular determinants underlying the formation of stable intracellular G protein-coupled receptor-\u03b2-arrestin complexes after receptor endocytosis","volume":"276","author":"Oakley","year":"2001","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib329","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.tips.2017.09.004","article-title":"Temporal bias: time-encoded dynamic GPCR signaling","volume":"38","author":"Grundmann","year":"2017","journal-title":"Trends Pharmacol Sci"},{"issue":"6054","key":"10.1016\/j.pharmr.2026.100160_bib330","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/319600a0","article-title":"Repetitive transient rises in cytoplasmic free calcium in hormone-stimulated hepatocytes","volume":"319","author":"Woods","year":"1986","journal-title":"Nature"},{"issue":"4989","key":"10.1016\/j.pharmr.2026.100160_bib331","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.1986413","article-title":"Generation of calcium oscillations in fibroblasts by positive feedback between calcium and IP3","volume":"251","author":"Harootunian","year":"1991","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib332","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81763-8","article-title":"Protein kinase C as a molecular machine for decoding calcium and diacylglycerol signals","volume":"95","author":"Oancea","year":"1998","journal-title":"Cell"},{"issue":"25","key":"10.1016\/j.pharmr.2026.100160_bib333","doi-asserted-by":"crossref","first-page":"14522","DOI":"10.1073\/pnas.2001270117","article-title":"GPCR-dependent biasing of GIRK channel signaling dynamics by RGS6 in mouse sinoatrial nodal cells","volume":"117","author":"Anderson","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100160_bib334","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/sj.onc.1209408","article-title":"Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells","volume":"25","author":"Cao","year":"2006","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib335","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.neuron.2006.07.010","article-title":"RGS expression rate-limits recovery of rod photoresponses","volume":"51","author":"Krispel","year":"2006","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib336","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/ncb3307","article-title":"\u03b2-arrestin drives MAP kinase signalling from clathrin-coated structures after GPCR dissociation","volume":"18","author":"Eichel","year":"2016","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100160_bib337","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1074\/jbc.R114.617951","article-title":"G protein-coupled receptor (GPCR) signaling via heterotrimeric G proteins from endosomes","volume":"290","author":"Tsvetanova","year":"2015","journal-title":"J Biol Chem"},{"issue":"40","key":"10.1016\/j.pharmr.2026.100160_bib338","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404243121","article-title":"Subcellular activation of \u03b2-adrenergic receptors using a spatially restricted antagonist","volume":"121","author":"Liccardo","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib339","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.75468","article-title":"The organic cation transporter 2 regulates dopamine D1 receptor signaling at the Golgi apparatus","volume":"11","author":"Puri","year":"2022","journal-title":"Elife"},{"issue":"392","key":"10.1016\/j.pharmr.2026.100160_bib340","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3447","article-title":"Neurokinin 1 receptor signaling in endosomes mediates sustained nociception and is a viable therapeutic target for prolonged pain relief","volume":"9","author":"Jensen","year":"2017","journal-title":"Sci Transl Med"},{"issue":"46","key":"10.1016\/j.pharmr.2026.100160_bib341","doi-asserted-by":"crossref","first-page":"12309","DOI":"10.1073\/pnas.1706656114","article-title":"Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission","volume":"114","author":"Yarwood","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100160_bib342","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/bph.15962","article-title":"Advancements in G protein-coupled receptor biosensors to study GPCR-G protein coupling","volume":"180","author":"Olsen","year":"2023","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib343","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.cell.2024.01.028","article-title":"Direct interrogation of context-dependent GPCR activity with a universal biosensor platform","volume":"187","author":"Janicot","year":"2024","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib344","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.cell.2020.06.020","article-title":"Revealing the activity of trimeric G-proteins in live cells with a versatile biosensor design","volume":"182","author":"Maziarz","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2026.100160_bib345","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ymeth.2021.05.002","article-title":"In vivo detection of GPCR-dependent signaling using fiber photometry and FRET-based biosensors","volume":"203","author":"Jones-Tabah","year":"2022","journal-title":"Methods"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib346","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.neuron.2020.09.036","article-title":"Imaging neurotransmitter and neuromodulator dynamics in vivo with genetically encoded indicators","volume":"108","author":"Sabatini","year":"2020","journal-title":"Neuron"},{"issue":"7241","key":"10.1016\/j.pharmr.2026.100160_bib347","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/nature07926","article-title":"Temporally precise in vivo control of intracellular signalling","volume":"458","author":"Airan","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib348","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202107135","article-title":"Assessing Gq-GPCR-induced human astrocyte reactivity using bioengineered neural organoids","volume":"221","author":"Cvetkovic","year":"2022","journal-title":"J Cell Biol"},{"key":"10.1016\/j.pharmr.2026.100160_bib349","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fcell.2015.00076","article-title":"G-protein coupled receptor signaling in pluripotent stem cell-derived cardiovascular cells: implications for disease modeling","volume":"3","author":"Dolatshad","year":"2015","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib350","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.yjmcc.2010.10.029","article-title":"Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy?","volume":"50","author":"F\u00f6ldes","year":"2011","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib351","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001263","article-title":"Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes","volume":"3","author":"Tanaka","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"130","key":"10.1016\/j.pharmr.2026.100160_bib352","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003552","article-title":"Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy","volume":"4","author":"Sun","year":"2012","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib353","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/eurheartj\/ehr073","article-title":"Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation","volume":"32","author":"Matsa","year":"2011","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib354","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-47388-x","article-title":"High-throughput identification of peptide agonists against GPCRs by co-culture of mammalian reporter cells and peptide-secreting yeast cells using droplet microfluidics","volume":"9","author":"Yaginuma","year":"2019","journal-title":"Sci Rep"},{"issue":"703","key":"10.1016\/j.pharmr.2026.100160_bib355","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abc8579","article-title":"Systems approach reveals distinct and shared signaling networks of the 4 PGE2 receptors in T cells","volume":"14","author":"Lone","year":"2021","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib356","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100907","article-title":"Endosomal cAMP production broadly impacts the cellular phosphoproteome","volume":"297","author":"Tsvetanova","year":"2021","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmr.2026.100160_bib357","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1146\/annurev-pharmtox-052120-011012","article-title":"Systems biology of the vasopressin V2 receptor: new tools for discovery of molecular actions of a GPCR","volume":"62","author":"Chen","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib358","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s42256-019-0048-x","article-title":"Stop explaining Black box machine learning models for high-stakes decisions and use interpretable models instead","volume":"1","author":"Rudin","year":"2019","journal-title":"Nat Mach Intell"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib359","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","article-title":"Impact of GPCR structures on drug discovery","volume":"181","author":"Congreve","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.pharmr.2026.100160_bib360","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108786","article-title":"Biased signaling in GPCRs: structural insights and implications for drug development","volume":"266","author":"Ma","year":"2025","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib361","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/acs.jmedchem.6b01453","article-title":"Recent Advances in Structure-Based Drug Design Targeting Class A G protein-coupled receptors utilizing crystal structures and computational simulations","volume":"61","author":"Lee","year":"2018","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib362","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tips.2022.12.006","article-title":"Targeting in silico GPCR conformations with ultra-large library screening for hit discovery","volume":"44","author":"Sala","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2026.100160_bib363","series-title":"Pharmacology in Drug Discovery and Development: Understanding Drug Response","author":"Deakin","year":"2017"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100160_bib364","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.1074\/jbc.R112.355461","article-title":"Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development","volume":"287","author":"O\u2019Callaghan","year":"2012","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib365","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3109\/10799893.2013.769004","article-title":"Emergent biological properties of arrestin pathway-selective biased agonism","volume":"33","author":"Appleton","year":"2013","journal-title":"J Recept Signal Transduct Res"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib366","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000071","article-title":"A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation","volume":"1","author":"Gesty-Palmer","year":"2009","journal-title":"Sci Transl Med"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100160_bib367","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2500176122","article-title":"A mouse model of Jansen\u2019s metaphyseal chondrodysplasia for investigating disease mechanisms and candidate therapeutics","volume":"122","author":"H\u00f6ppner","year":"2025","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib368","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.784947","article-title":"Humanized mice as a valuable pre-clinical model for cancer immunotherapy research","volume":"11","author":"Cogels","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.pharmr.2026.100160_bib369","article-title":"An Online Biased Signaling Atlas","author":"Caroli","year":"2022","journal-title":"Research Square"},{"issue":"14","key":"10.1016\/j.pharmr.2026.100160_bib370","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1111\/bph.17301","article-title":"Progress on the development of Class A GPCR-biased ligands","volume":"182","author":"Morales","year":"2025","journal-title":"Br J Pharmacol"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100160_bib371","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1007\/s40265-020-01414-9","article-title":"Oliceridine: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.pharmr.2026.100160_bib372","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"Viscusi","year":"2019","journal-title":"J Pain Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib373","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/papr.12801","article-title":"APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u03bc-opioid receptor, for management of moderate to severe acute pain following abdominoplasty","volume":"19","author":"Singla","year":"2019","journal-title":"Pain Pract"},{"key":"10.1016\/j.pharmr.2026.100160_bib374","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.2147\/JPR.S217563","article-title":"Athena: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), a G-protein-selective agonist at the micro-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy","volume":"12","author":"Bergese","year":"2019","journal-title":"J Pain Res"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100160_bib375","doi-asserted-by":"crossref","first-page":"12435","DOI":"10.1073\/pnas.1920310117","article-title":"The beta-arrestin-biased beta-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility","volume":"117","author":"Kim","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib376","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41467-017-01855-z","article-title":"G\u03b1i is required for carvedilol-induced \u03b21 adrenergic receptor beta-arrestin biased signaling","volume":"8","author":"Wang","year":"2017","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib377","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071980","article-title":"The beta-blocker nebivolol Is a GRK\/beta-arrestin-biased agonist","volume":"8","author":"Erickson","year":"2013","journal-title":"PLoS One"},{"issue":"20","key":"10.1016\/j.pharmr.2026.100160_bib378","doi-asserted-by":"crossref","first-page":"11406","DOI":"10.1073\/pnas.1936664100","article-title":"Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors","volume":"100","author":"Azzi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib379","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bph.15497","article-title":"The therapeutic potential of GLP-1 receptor biased agonism","volume":"179","author":"Jones","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100160_bib380","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib381","article-title":"Biased agonism of GLP-1R and GIPR enhances glucose lowering and weight loss, with dual GLP-1R\/GIPR biased agonism yielding greater efficacy","volume":"6","author":"Rodriguez","year":"2025","journal-title":"Cell Rep Med"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib382","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide Once Weekly in Patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib383","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once Weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.pharmr.2026.100160_bib384","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib385","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"issue":"10534","key":"10.1016\/j.pharmr.2026.100160_bib386","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(26)00202-3","article-title":"Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial","volume":"407","author":"Rosenstock","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib387","doi-asserted-by":"crossref","first-page":"6243","DOI":"10.1038\/s41467-023-41893-4","article-title":"GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics","volume":"14","author":"Wright","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib388","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1210\/en.2011-1426","article-title":"Positive and negative allosteric modulators promote biased signaling at the calcium-sensing receptor","volume":"153","author":"Davey","year":"2012","journal-title":"Endocrinology"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100160_bib389","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of Cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib390","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1210\/en.2012-1887","article-title":"Impact of clinically relevant mutations on the pharmacoregulation and signaling bias of the calcium-sensing receptor by positive and negative allosteric modulators","volume":"154","author":"Leach","year":"2013","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib391","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bph.12937","article-title":"Biased allosteric modulation at the CaS receptor engendered by structurally diverse calcimimetics","volume":"172","author":"Cook","year":"2015","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib392","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/jpet.120.000134","article-title":"Strategies for developing kappa opioid receptor agonists for the treatment of pain with fewer side effects","volume":"375","author":"Paton","year":"2020","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib393","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.pharmr.2026.100160_bib394","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fphar.2019.00407","article-title":"A review of the therapeutic potential of recently developed G protein-biased kappa agonists","volume":"10","author":"Mores","year":"2019","journal-title":"Front Pharmacol"},{"issue":"29","key":"10.1016\/j.pharmr.2026.100160_bib395","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1021\/bi900605n","article-title":"Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor","volume":"48","author":"Yan","year":"2009","journal-title":"Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib396","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1124\/jpet.114.216820","article-title":"The G protein-biased \u03ba-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo","volume":"352","author":"White","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"456","key":"10.1016\/j.pharmr.2026.100160_bib397","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aai8441","article-title":"Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria","volume":"9","author":"Brust","year":"2016","journal-title":"Sci Signal"},{"key":"10.1016\/j.pharmr.2026.100160_bib398","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2022.173394","article-title":"The G-protein biased kappa opioid agonists, triazole 1.1 and nalfurafine, produce non-uniform behavioral effects in male rhesus monkeys","volume":"217","author":"Huskinson","year":"2022","journal-title":"Pharmacol Biochem Behav"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib399","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/jcph.111","article-title":"First clinical experience with TRV027: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"53","author":"Soergel","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"30","key":"10.1016\/j.pharmr.2026.100160_bib400","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/eurheartj\/ehx196","article-title":"Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF)","volume":"38","author":"Pang","year":"2017","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.pharmr.2026.100160_bib401","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacbts.2021.09.006","article-title":"Beta-arrestin-mediated angiotensin II type 1 receptor activation promotes pulmonary vascular remodeling in pulmonary hypertension","volume":"6","author":"Ma","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"26","key":"10.1016\/j.pharmr.2026.100160_bib402","doi-asserted-by":"crossref","first-page":"5237","DOI":"10.1182\/blood-2012-08-452169","article-title":"Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46","volume":"120","author":"Mosnier","year":"2012","journal-title":"Blood"},{"issue":"50","key":"10.1016\/j.pharmr.2026.100160_bib403","doi-asserted-by":"crossref","first-page":"E1372","DOI":"10.1073\/pnas.1112482108","article-title":"Activated protein C promotes protease-activated receptor-1 cytoprotective signaling through beta-arrestin and dishevelled-2 scaffolds","volume":"108","author":"Soh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib404","doi-asserted-by":"crossref","first-page":"E982","DOI":"10.1073\/pnas.1718600115","article-title":"PAR1 agonists stimulate APC-like endothelial cytoprotection and confer resistance to thromboinflammatory injury","volume":"115","author":"De Ceunynck","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharmr.2026.100160_bib405","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3389\/fnins.2020.00335","article-title":"New PAR1 agonist peptide demonstrates protective action in a mouse model of photothrombosis-induced brain ischemia","volume":"14","author":"Galkov","year":"2020","journal-title":"Front Neurosci"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib406","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2014-09-599910","article-title":"Parmodulins inhibit thrombus formation without inducing endothelial injury caused by vorapaxar","volume":"125","author":"Aisiku","year":"2015","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100160_bib407","first-page":"2675","article-title":"Targeting biased signaling by PAR1: function and molecular mechanism of parmodulins","volume":"141","author":"K\u00fcnze","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pharmr.2026.100160_bib408","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109862","article-title":"Biased agonism at chemokine receptors","volume":"78","author":"Eiger","year":"2021","journal-title":"Cell Signal"},{"issue":"42","key":"10.1016\/j.pharmr.2026.100160_bib409","first-page":"414","article-title":"Biased Agonism as a mechanism for differential signaling by chemokine receptors","volume":"288","author":"Rajagopal","year":"2013","journal-title":"J Biol Chem"},{"issue":"15","key":"10.1016\/j.pharmr.2026.100160_bib410","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1074\/jbc.M114.596098","article-title":"Biased signaling at chemokine receptors","volume":"290","author":"Corbisier","year":"2015","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.pharmr.2026.100160_bib411","doi-asserted-by":"crossref","first-page":"23214","DOI":"10.1074\/jbc.M402125200","article-title":"Differential desensitization, receptor phosphorylation, beta-arrestin recruitment, and ERK1\/2 activation by the two endogenous ligands for the CC chemokine receptor 7","volume":"279","author":"Kohout","year":"2004","journal-title":"J Biol Chem"},{"issue":"552","key":"10.1016\/j.pharmr.2026.100160_bib412","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aao6152","article-title":"G protein subtype-specific signaling bias in a series of CCR5 chemokine analogs","volume":"11","author":"Lorenzen","year":"2018","journal-title":"Sci Signal"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib413","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2014.11.009","article-title":"CXCR3 ligands in disease and therapy","volume":"26","author":"Van Raemdonck","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib414","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1038\/s41467-025-58264-w","article-title":"Structural visualization of small molecule recognition by CXCR3 uncovers dual-agonism in the CXCR3-CXCR7 system","volume":"16","author":"Saha","year":"2025","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib415","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.biopsych.2016.10.011","article-title":"New concepts in dopamine D2 receptor biased signaling and implications for schizophrenia therapy","volume":"81","author":"Urs","year":"2017","journal-title":"Biol Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib416","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1038\/s41380-023-02203-y","article-title":"Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis","volume":"28","author":"Siafis","year":"2023","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmr.2026.100160_bib417","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/npp.2015.196","article-title":"Effects of beta-arrestin-biased dopamine D2 receptor ligands on schizophrenia-like behavior in Hypoglutamatergic mice","volume":"41","author":"Park","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"10.1016\/j.pharmr.2026.100160_bib418","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyae060","article-title":"Combination of haloperidol with UNC9994, \u03b2-arrestin-biased analog of aripiprazole, ameliorates schizophrenia-related phenotypes induced by NMDAR deficit in mice","volume":"27","author":"Lipina","year":"2024","journal-title":"Int J Neuropsychopharmacol"},{"issue":"23","key":"10.1016\/j.pharmr.2026.100160_bib419","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1021\/acs.jmedchem.6b01208","article-title":"Discovery of G protein-biased D2 dopamine receptor partial agonists","volume":"59","author":"Chen","year":"2016","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib420","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1021\/acs.jmedchem.9b00508","article-title":"D(2) dopamine receptor G protein-biased partial agonists based on cariprazine","volume":"62","author":"Shen","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmr.2026.100160_bib421","article-title":"Fine tuning muscarinic acetylcholine receptor signaling through allostery and bias","volume":"11","author":"van der Westhuizen","year":"2020","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib422","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd4295","article-title":"Muscarinic acetylcholine receptors: novel opportunities for drug development","volume":"13","author":"Kruse","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib423","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib424","doi-asserted-by":"crossref","first-page":"7356","DOI":"10.3390\/ijms24087356","article-title":"Structural Insights into M1 muscarinic acetylcholine receptor signaling bias between G\u03b1q and \u03b2-arrestin through BRET assays and molecular docking","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib425","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1021\/acschemneuro.1c00827","article-title":"Biased Profile of xanomeline at the recombinant human M4 muscarinic acetylcholine receptor","volume":"13","author":"McDonald","year":"2022","journal-title":"ACS Chem Neurosci"},{"issue":"10422","key":"10.1016\/j.pharmr.2026.100160_bib426","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib427","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/jamapsychiatry.2024.0785","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.pharmr.2026.100160_bib428","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N Engl J Med"},{"issue":"610","key":"10.1016\/j.pharmr.2026.100160_bib429","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aax2057","article-title":"Biased M1 receptor-positive allosteric modulators reveal role of phospholipase D in M(1)-dependent rodent cortical plasticity","volume":"12","author":"Moran","year":"2019","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib430","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.trci.2018.03.004","article-title":"Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer\u2019s disease","volume":"4","author":"Voss","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"issue":"10369","key":"10.1016\/j.pharmr.2026.100160_bib431","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/S0140-6736(22)01990-0","article-title":"Emraclidine, a novel positive allosteric modulator of cholinergic M4 receptors, for the treatment of schizophrenia: a two-part, randomised, double-blind, placebo-controlled, phase 1b trial","volume":"400","author":"Krystal","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib432","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1139\/jpn.0627","article-title":"The role of neurotensin in central nervous system pathophysiology: what is the evidence?","volume":"31","author":"St-Gelais","year":"2006","journal-title":"J Psychiatry Neurosci"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib433","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1080\/13543776.2021.1866539","article-title":"Therapeutic approaches targeting the neurotensin receptors","volume":"31","author":"Iyer","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.pharmr.2026.100160_bib434","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fendo.2013.00036","article-title":"Diverse roles of neurotensin agonists in the central nervous system","volume":"4","author":"Boules","year":"2013","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib435","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/sj.npp.1300494","article-title":"The neurotensin agonist PD149163 increases Fos expression in the prefrontal cortex of the rat","volume":"29","author":"Petrie","year":"2004","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib436","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.pbb.2008.05.025","article-title":"The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle","volume":"90","author":"Shilling","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pharmr.2026.100160_bib437","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbr.2016.02.019","article-title":"Antipsychotic-like effects of a neurotensin receptor type 1 agonist","volume":"305","author":"Vadnie","year":"2016","journal-title":"Behav Brain Res"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib438","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ddr.21393","article-title":"The neurotensin NTS1 receptor agonist PD149163 produces antidepressant-like effects in the forced swim test: further support for neurotensin as a novel pharmacologic strategy for antidepressant drugs","volume":"78","author":"Carey","year":"2017","journal-title":"Drug Dev Res"},{"issue":"7","key":"10.1016\/j.pharmr.2026.100160_bib439","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1021\/acschembio.6b00291","article-title":"ML314: a biased neurotensin receptor ligand for methamphetamine abuse","volume":"11","author":"Barak","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"17","key":"10.1016\/j.pharmr.2026.100160_bib440","doi-asserted-by":"crossref","first-page":"8357","DOI":"10.1021\/acs.jmedchem.9b00340","article-title":"Discovery of \u03b2-arrestin biased, orally bioavailable, and CNS penetrant neurotensin receptor 1 (NTR1) allosteric modulators","volume":"62","author":"Pinkerton","year":"2019","journal-title":"J Med Chem"},{"issue":"16","key":"10.1016\/j.pharmr.2026.100160_bib441","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1016\/j.cell.2025.04.038","article-title":"Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain","volume":"188","author":"Guo","year":"2025","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pharmr.2026.100160_bib442","first-page":"607","article-title":"Review of the endocannabinoid system","volume":"6","author":"Lu","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"issue":"1","key":"10.1016\/j.pharmr.2026.100160_bib443","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90167-w","article-title":"Assessment of select synthetic cannabinoid receptor agonist bias and selectivity between the type 1 and type 2 cannabinoid receptor","volume":"11","author":"Zagzoog","year":"2021","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.pharmr.2026.100160_bib444","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1021\/acsptsci.9b00069","article-title":"Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds","volume":"3","author":"Wouters","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"45","key":"10.1016\/j.pharmr.2026.100160_bib445","doi-asserted-by":"crossref","first-page":"27021","DOI":"10.1074\/jbc.M115.659250","article-title":"Agonism, antagonism, and inverse agonism bias at the ghrelin receptor signaling","volume":"290","author":"M\u2019Kadmi","year":"2015","journal-title":"J Biol Chem"},{"issue":"9","key":"10.1016\/j.pharmr.2026.100160_bib446","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.tips.2015.06.002","article-title":"Apelin, Elabela\/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system","volume":"36","author":"Yang","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2026.100160_bib447","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.109954","article-title":"Biased agonism at adenosine receptors","volume":"82","author":"McNeill","year":"2021","journal-title":"Cell Signal"},{"issue":"5","key":"10.1016\/j.pharmr.2026.100160_bib448","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1124\/mol.116.105981","article-title":"Current Knowledge and Perspectives on histamine H1 and H2 receptor pharmacology: functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands","volume":"90","author":"Monczor","year":"2016","journal-title":"Mol Pharmacol"},{"issue":"4","key":"10.1016\/j.pharmr.2026.100160_bib449","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.tibs.2024.01.010","article-title":"Oxytocin and vasopressin signaling in health and disease","volume":"49","author":"Perisic","year":"2024","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.pharmr.2026.100160_bib450","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.lfs.2016.02.069","article-title":"Evidence for biased agonists and antagonists at the endothelin receptors","volume":"159","author":"Maguire","year":"2016","journal-title":"Life Sci"},{"issue":"6463","key":"10.1016\/j.pharmr.2026.100160_bib451","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar5551","article-title":"Sphingosine 1-phosphate: lipid signaling in pathology and therapy","volume":"366","author":"Cartier","year":"2019","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.pharmr.2026.100160_bib452","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.tips.2019.08.005","article-title":"Towards targeting the urotensinergic system: overview and challenges","volume":"40","author":"Nassour","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pharmr.2026.100160_bib453","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuropharm.2016.07.001","article-title":"Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: implications for optimizing preclinical neuroscience drug discovery","volume":"115","author":"Sengmany","year":"2017","journal-title":"Neuropharmacology"},{"issue":"21","key":"10.1016\/j.pharmr.2026.100160_bib454","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1042\/CS20180374","article-title":"Biased agonism and allosteric modulation of metabotropic glutamate receptor 5","volume":"132","author":"Trinh","year":"2018","journal-title":"Clin Sci (Lond)"},{"issue":"10 Pt A","key":"10.1016\/j.pharmr.2026.100160_bib455","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1016\/j.bbadis.2017.04.010","article-title":"Biased signaling at neural melanocortin receptors in regulation of energy homeostasis","volume":"1863","author":"Yang","year":"2017","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699726000487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:19:03Z","timestamp":1790241543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699726000487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":455,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0031699726000487"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100160","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The promise of biased ligands in therapeutics","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmr.2026.100160","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100160"}}